Cadiz (CDZI) Reports Q1 Loss, Misses Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy LVRO?
Source: NASDAQ.COM
Quarterly Performance: Cadiz (CDZI) reported a quarterly loss of $0.14 per share, missing the Zacks Consensus Estimate of a loss of $0.11, and has not surpassed consensus EPS estimates in the last four quarters. The company's revenues of $2.95 million also fell short of expectations by 34.14%.
Market Outlook: Cadiz shares have declined by about 39% this year, and the current unfavorable estimate revisions trend results in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future. Investors are advised to monitor changes in earnings estimates for upcoming quarters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LVRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LVRO
About LVRO
Lavoro Limited is a Brazil-based agricultural input retailer and a provider of agriculture biologics inputs. The Company has three reportable segments: the Brazil Cluster, which comprises companies dedicated to the distribution of agricultural inputs such as crop protection, seeds, fertilizers and specialty products, in Brazil; the LATAM Cluster, which includes companies dedicated to the distribution ofagricultural inputs outside Brazil primarily in Colombia; as well as the Crop Care Cluster, which includes companies that produce and import Lavoro's own portfolio of private label products including off-patent crop protection and specialty products, e.g., biologicals and specialty fertilizers. The main crops served are: soy, corn, cotton, coffee, beans, rice, sugar cane, wheat, citrus and pastures. The Company has a broad geographical presence, operating in Brazil, Colombia, and Uruguay.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lavoro Announces Voluntary Delisting from Nasdaq
- Voluntary Delisting Decision: Lavoro Limited has announced its intention to voluntarily delist its ordinary shares and warrants, with a Form 25 filing expected on February 24, 2026, reflecting the company's operational challenges and cost pressures amid a difficult market environment in Brazil.
- Liquidity Issues: The company's low trading volume and limited public shareholder base have severely impacted the liquidity of its securities, restricting its ability to access U.S. capital markets and making it difficult to attract interest from institutional investors and market analysts.
- High Compliance Costs: Lavoro continues to incur significant audit, legal, and compliance costs associated with being a publicly traded company, particularly under the Sarbanes-Oxley Act, leading to an operational burden that outweighs the potential benefits of maintaining a public listing.
- Change in Trading Methods: Following the delisting, trading of Lavoro's ordinary shares and warrants will only occur through privately negotiated sales or potentially on an over-the-counter market, with no guarantee that a broker will provide a market, which may further affect investor liquidity and trading opportunities.
See More
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
New Fortress Energy Shares Surge 41%; Check Out 20 Stocks Making Moves in Premarket Trading
New Fortress Energy Agreement: New Fortress Energy Inc. shares surged 41% in pre-market trading after announcing a long-term liquefied natural gas supply agreement with the Puerto Rican government.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with SciSparc Ltd. gaining 186.2% and Co-Diagnostics, Inc. dropping 29.2% following recent developments.
See More
Webtoon Entertainment Shares Surge 48%; Check Out 20 Stocks Making Moves in Premarket Trading
Webtoon Entertainment Partnership: Webtoon Entertainment Inc's shares surged 47.8% in pre-market trading after announcing a partnership with The Walt Disney Co to create a digital comics platform featuring Marvel, Star Wars, Pixar, and Disney titles.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with FGI Industries Ltd gaining 185.2% and Conifer Holdings Inc rising 136.8%, while Apartment Investment and Management Company saw a decline of 9.4%.
See More
Lavoro Announces Voluntary Delisting from Nasdaq
- Voluntary Delisting Decision: Lavoro Limited has announced its intention to voluntarily delist its ordinary shares and warrants, with a Form 25 filing expected on February 24, 2026, reflecting the company's operational challenges and cost pressures amid a difficult market environment in Brazil.
- Liquidity Issues: The company's low trading volume and limited public shareholder base have severely impacted the liquidity of its securities, restricting its ability to access U.S. capital markets and making it difficult to attract interest from institutional investors and market analysts.
- High Compliance Costs: Lavoro continues to incur significant audit, legal, and compliance costs associated with being a publicly traded company, particularly under the Sarbanes-Oxley Act, leading to an operational burden that outweighs the potential benefits of maintaining a public listing.
- Change in Trading Methods: Following the delisting, trading of Lavoro's ordinary shares and warrants will only occur through privately negotiated sales or potentially on an over-the-counter market, with no guarantee that a broker will provide a market, which may further affect investor liquidity and trading opportunities.
See More
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
New Fortress Energy Shares Surge 41%; Check Out 20 Stocks Making Moves in Premarket Trading
New Fortress Energy Agreement: New Fortress Energy Inc. shares surged 41% in pre-market trading after announcing a long-term liquefied natural gas supply agreement with the Puerto Rican government.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with SciSparc Ltd. gaining 186.2% and Co-Diagnostics, Inc. dropping 29.2% following recent developments.
See More
Webtoon Entertainment Shares Surge 48%; Check Out 20 Stocks Making Moves in Premarket Trading
Webtoon Entertainment Partnership: Webtoon Entertainment Inc's shares surged 47.8% in pre-market trading after announcing a partnership with The Walt Disney Co to create a digital comics platform featuring Marvel, Star Wars, Pixar, and Disney titles.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with FGI Industries Ltd gaining 185.2% and Conifer Holdings Inc rising 136.8%, while Apartment Investment and Management Company saw a decline of 9.4%.
See More
